Tirzepatide and retatrutide both target GLP-1 pathways for weight loss, but retatrutide adds a third hormone receptor — glucagon — creating meaningful differences in mechanism, evidence, and who each medication may suit best. TelosRX breaks down what the research actually shows.
Tirzepatide is FDA-approved and widely available. Retatrutide is investigational — not FDA-approved — but has generated some of the highest weight-loss percentages reported in clinical trials to date. The core difference between them is a single added receptor pathway.
Here's what that difference means in practice.
Tirzepatide vs Retatrutide: Key Differences at a Glance
| Feature | Tirzepatide | Retatrutide |
|---|---|---|
| Mechanism | Dual agonist (GLP-1 + GIP receptors) | Triple agonist (GLP-1 + GIP + Glucagon receptors) |
| FDA Status | Approved (Zepbound / Mounjaro) | Investigational — not FDA-approved |
| Mean weight loss (highest dose) | Up to 20.9–22.5% at 72 weeks (Phase 3) | Up to 24.2% at 48 weeks (Phase 2); 28.7% at 68 weeks (Phase 3 interim) |
| Liver fat reduction | Significant improvement in most trials | Up to 85% hepatic steatosis resolution in Phase 2 subset data |
| Heart rate effect | Mild, transient | Dose-dependent increase peaking ~week 24, then declining |
| Administration | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection (in trials) |
| Compounded availability | Available subject to medical approval by a licensed provider | Compounded retatrutide is not FDA-approved; subject to provider evaluation |
| Evidence base | Phase 3 complete; 3-year extension data available | Phase 3 ongoing (TRIUMPH program); results expected late 2026 |
These weight-loss figures come from separate studies with different patient populations and timelines. A direct head-to-head trial (TRIUMPH-5) is ongoing, with results expected December 2026.
How Each Medication Works
Tirzepatide: Dual-Receptor Action
Tirzepatide binds both GLP-1 and GIP receptors simultaneously. GLP-1 (glucagon-like peptide-1) slows gastric emptying, reduces appetite, and stimulates insulin secretion in response to meals. GIP (glucose-dependent insulinotropic polypeptide) adds synergistic effects on fat storage regulation and energy metabolism.
The dual mechanism produced impressive results in the SURMOUNT-1 Phase 3 trial: mean weight reduction up to 20.9% at 72 weeks at the 15mg dose, with more than 60% of participants achieving 20%+ body weight loss. The FDA approved tirzepatide for chronic weight management (as Zepbound) and type 2 diabetes (as Mounjaro).
Retatrutide: Triple-Receptor Action
Retatrutide retains everything tirzepatide does, then adds glucagon receptor agonism. The glucagon component adds two meaningful effects: it increases energy expenditure at rest (your body burns more calories passively), and it targets hepatic fat directly.
In its NEJM-published Phase 2 obesity trial, participants on the 12mg dose achieved a mean 24.2% weight reduction at 48 weeks — and hadn't yet plateaued when the study ended. Eli Lilly announced Phase 3 TRIUMPH-4 interim results in December 2025: up to 28.7% mean weight loss at 68 weeks in patients with obesity and knee osteoarthritis.
These numbers are striking. But retatrutide is not FDA-approved, and Phase 3 data is still being published. The SURMOUNT-1 tirzepatide trial ran 72 weeks; the retatrutide 28.7% comes from a different patient population at 68 weeks. Direct comparison of percentages across different studies is not scientifically sound without controlling for those differences.
Side Effects: What Differs Between the Two
Both share the incretin-class GI side effect profile: nausea, diarrhea, constipation, and vomiting. These are dose-dependent and typically peak during the titration phase, then diminish with consistent dosing. They are not unique to either drug.
The meaningful differential for retatrutide is a transient, dose-dependent heart rate increase. In Phase 2 data, heart rate increases were observed, peaked around week 24, and then declined toward baseline. This makes cardiovascular screening especially important in a retatrutide evaluation.
- Tirzepatide: well-characterized safety profile from Phase 3 data and real-world clinical use
- Retatrutide: GI side effects comparable; adds the heart rate signal; long-term safety profile still being established in ongoing Phase 3
- Both: carry the class warning for GLP-1 receptor agonists regarding medullary thyroid carcinoma (personal or family history is a contraindication to consider)
Efficacy Beyond Weight: Liver and Metabolic Markers
Weight loss percentages are the headline, but metabolic outcomes tell the fuller story.
Tirzepatide: SURMOUNT-1 showed a 94% reduction in progression from pre-diabetes to type 2 diabetes over three years. Cardiometabolic markers (blood pressure, fasting glucose, triglycerides) improved substantially. DXSA body composition data showed approximately 75% of weight lost came from fat mass and 25% from lean mass.
Retatrutide: Phase 2 data showed strong improvements in cardiometabolic markers. The liver data is notable: in a subset analysis, retatrutide led to resolution of hepatic steatosis (fatty liver) in roughly 85% of participants at higher doses. The glucagon receptor component appears to drive this directly — an advantage over dual agonists for patients with significant liver fat involvement.
For more on muscle preservation during GLP-1 therapy, see our guide on muscle loss and lean mass on GLP-1 medications. Strategies discussed there — protein intake, resistance training, and potential peptide support — apply to both tirzepatide and retatrutide protocols.
Who Might Consider Tirzepatide
Tirzepatide is the better-characterized option with full Phase 3 data and FDA approval. It's the established choice for most people starting a GLP-1 program.
- Patients prioritizing proven Phase 3 evidence and real-world safety data
- Those with pre-diabetes or elevated blood glucose who want strong glycemic improvement alongside weight management
- Anyone who wants the lower-cost compounded option with the most clinical experience behind it
Compounded tirzepatide is available through TelosRX's asynchronous evaluation process — subject to medical approval by a licensed provider. Our guide to compounded tirzepatide via telehealth covers the process in detail.
Start your private evaluation at TelosRX to explore your options.
Who Might Consider Retatrutide
Retatrutide's additional glucagon receptor pathway may offer advantages in specific metabolic situations. The evidence is compelling but still Phase 3-incomplete.
- Patients with significant hepatic steatosis (fatty liver): the glucagon component appears potently active on liver fat
- Those who plateaued on a GLP-1 or dual agonist at optimal dosing and are considering the next tier of efficacy
- Patients for whom the additional energy expenditure effect of glucagon agonism is clinically relevant — particularly in cases of metabolic syndrome with a sluggish metabolic rate
Because retatrutide is not FDA-approved, compounded retatrutide is also not FDA-approved. Access requires evaluation and approval by a licensed provider through an asynchronous process. No real-time call is required at TelosRX — your evaluation is reviewed at your pace.
Cost and Access: The Practical Picture
Tirzepatide (Zepbound) carries a high brand-name list price. Compounded tirzepatide is significantly more affordable for eligible patients and is available now, subject to provider approval following an asynchronous telehealth evaluation.
Retatrutide is not commercially available. It is available through clinical trials and — for eligible patients subject to provider evaluation — through compounding pharmacies operating under federal compounding regulations. Eli Lilly's regulatory submission is anticipated following Phase 3 completion.
TelosRX operates as an online-first, asynchronous telehealth service. No in-person visits. No scheduled phone calls. Your evaluation is reviewed by a licensed provider at a time that suits you.
Frequently Asked Questions
Is retatrutide better than tirzepatide?
Retatrutide has shown higher mean weight-loss percentages in clinical trials to date. But these are separate studies — not a direct head-to-head comparison. Tirzepatide has significantly more Phase 3 data and real-world experience. Which is "better" depends entirely on your specific health profile, goals, and the provider's evaluation of your case.
Is retatrutide FDA-approved?
No. As of September 2026, retatrutide is investigational. Eli Lilly's TRIUMPH Phase 3 program is ongoing, and an FDA submission is anticipated following program completion. Compounded retatrutide is also not FDA-approved.
What is the difference between dual and triple agonism?
Tirzepatide activates GLP-1 and GIP receptors. Retatrutide activates those two plus the glucagon receptor. The added glucagon pathway is studied primarily for increased resting energy expenditure and direct liver fat reduction — effects tirzepatide produces less directly.
Can I get compounded tirzepatide or retatrutide through telehealth?
Compounded versions of both are prepared under federal compounding regulations and are not FDA-approved. Access requires evaluation and approval by a licensed provider through an asynchronous telehealth evaluation. TelosRX facilitates this fully online, with no live calls required.
What are the main side effects of retatrutide vs tirzepatide?
Both cause GI side effects (nausea, diarrhea, constipation) that are dose-related and typically improve during titration. Retatrutide additionally showed dose-dependent heart rate increases in Phase 2, peaking around week 24. Cardiovascular screening is especially important with retatrutide evaluation.
How much weight loss does tirzepatide produce?
In the SURMOUNT-1 Phase 3 trial, participants at the 15mg dose achieved a mean 20.9–22.5% weight reduction at 72 weeks. Individual results vary significantly and depend on adherence, lifestyle, and baseline health factors. Results are subject to provider evaluation and approval.
What does retatrutide do for the liver?
In Phase 2 data, retatrutide led to resolution of hepatic steatosis in roughly 85% of participants at higher doses in a subset analysis. The glucagon receptor component drives this liver-specific effect — making retatrutide a particularly interesting option for patients with fatty liver, pending FDA approval.
Does retatrutide have more side effects than tirzepatide?
Core GI side effects are similar between both. Retatrutide adds a transient heart rate increase not seen as prominently with tirzepatide. Long-term safety data for retatrutide is still being collected in ongoing Phase 3 trials, so the full picture isn't yet finalized.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.